派林生物
(000403)
| 流通市值：205.48亿 | | | 总市值：218.94亿 |
| 流通股本：6.88亿 | | | 总股本：7.33亿 |
| 报告期 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,374,813,312.16 | 709,071,800.34 | 260,860,262.39 | 2,405,188,425.37 |
| 营业收入 | 1,374,813,312.16 | 709,071,800.34 | 260,860,262.39 | 2,405,188,425.37 |
| 二、营业总成本 | 1,033,269,820.34 | 572,349,333.11 | 218,309,593.81 | 1,753,334,080.51 |
| 营业成本 | 686,742,641.68 | 363,415,906.98 | 134,577,337.57 | 1,151,443,270.29 |
| 税金及附加 | 11,711,380.56 | 6,630,641.45 | 2,812,960.95 | 16,795,116.03 |
| 销售费用 | 202,257,175.81 | 121,013,394.93 | 41,433,502.19 | 399,568,789.11 |
| 管理费用 | 121,648,000.2 | 81,307,617.76 | 38,862,602.31 | 165,477,015.71 |
| 研发费用 | 53,761,401.55 | 29,374,532.76 | 14,274,385.64 | 75,364,822.96 |
| 财务费用 | -42,850,779.46 | -29,392,760.77 | -13,651,194.85 | -55,314,933.59 |
| 其中:利息费用 | 6,195,904.02 | 4,473,100.56 | 2,457,191.15 | 12,025,699.39 |
| 其中:利息收入 | 50,319,998.89 | 34,080,972.36 | 16,440,642.57 | 65,179,142.65 |
| 加:公允价值变动收益 | 8,947,345.72 | 5,656,024.04 | 2,735,457.88 | 4,929,120.51 |
| 加:投资收益 | 4,357,180.64 | 2,593,788.88 | 616,694.45 | 3,037,839.67 |
| 资产处置收益 | 12,023.17 | 12,023.17 | 538.03 | 438,082.69 |
| 资产减值损失(新) | - | - | - | 124,406.76 |
| 信用减值损失(新) | 8,065,349.87 | 8,969,953.01 | 12,061,663.28 | -11,816,519.3 |
| 其他收益 | 9,710,172.68 | 7,409,260.43 | 5,208,458.9 | 14,862,220.9 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 372,635,563.9 | 161,363,516.76 | 63,173,481.12 | 663,429,496.09 |
| 加:营业外收入 | 3,283,390.69 | 1,075,135.06 | 190.43 | 2,515,190.12 |
| 减:营业外支出 | 5,849,963.67 | 3,109,334.41 | 256,781.2 | 5,552,547.08 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 370,068,990.92 | 159,329,317.41 | 62,916,890.35 | 660,392,139.13 |
| 减:所得税费用 | 44,255,671.13 | 16,328,318.47 | 6,698,573.43 | 72,701,998.9 |
| 六、净利润 | 325,813,319.79 | 143,000,998.94 | 56,218,316.92 | 587,690,140.23 |
| 持续经营净利润 | 325,813,319.79 | 143,000,998.94 | 56,218,316.92 | 587,690,140.23 |
| 归属于母公司股东的净利润 | 326,195,419.81 | 143,137,171.51 | 56,376,087.53 | 587,131,491.86 |
| 少数股东损益 | -382,100.02 | -136,172.57 | -157,770.61 | 558,648.37 |
| (一)基本每股收益 | 0.45 | 0.2 | 0.08 | 0.8 |
| (二)稀释每股收益 | 0.45 | 0.2 | 0.08 | 0.8 |
| 八、其他综合收益 | 20,987.35 | 25,570.44 | -9,140.31 | 35,642.15 |
| 归属于母公司股东的其他综合收益 | 20,987.35 | 25,570.44 | -9,140.31 | 35,642.15 |
| 九、综合收益总额 | 325,834,307.14 | 143,026,569.38 | 56,209,176.61 | 587,725,782.38 |
| 归属于母公司股东的综合收益总额 | 326,216,407.16 | 143,162,741.95 | 56,366,947.22 | 587,167,134.01 |
| 归属于少数股东的综合收益总额 | -382,100.02 | -136,172.57 | -157,770.61 | 558,648.37 |
| 公告日期 | 2023-10-31 | 2023-08-24 | 2023-04-29 | 2023-04-29 |
| 审计意见(境内) | | | | 标准无保留意见 |